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In follicular lymphoma, studies addressing the prognostic value ofmicroenvironment-related immunohistochemical markers and tumorcell-related genetic markers have yielded conflicting results, preclud-
ing implementation in practice. Therefore, the Lunenburg Lymphoma
Biomarker Consortium performed a validation study evaluating pub-
lished markers. To maximize sensitivity, an end of spectrum design was
applied for 122 uniformly immunochemotherapy-treated follicular lym-
phoma patients retrieved from international trials and registries. The cri-
teria were: early failure, progression or lymphoma-related death <2
years versus long remission, response duration of >5 years.
Immunohistochemical staining for T cells and macrophages was per-
formed on tissue microarrays from initial biopsies and scored with a val-
idated computer-assisted protocol. Shallow whole-genome and deep
targeted sequencing was performed on the same samples. The 96/122
cases with complete molecular and immunohistochemical data were
included in the analysis. EZH2 wild-type (P=0.006), gain of chromo-
some 18 (P=0.002), low percentages of CD8+ cells (P=0.011) and
CD163+ areas (P=0.038) were associated with early failure. No signifi-
cant differences in other markers were observed, thereby refuting previ-
ous claims of their prognostic significance.   Using an optimized study
design, this Lunenburg Lymphoma Biomarker Consortium study sub-
stantiates wild-type EZH2 status, gain of chromosome 18, low percent-
ages of CD8+ cells and CD163+ area as predictors of early failure to
immunochemotherapy in follicular lymphoma treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP
[-like]), while refuting the prognostic impact of various other markers.  
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ABSTRACT
Introduction
The disease course of follicular lymphoma (FL) is char-
acterized by multiple relapses with variable remission
durations, which tend to get shorter after each line of
treatment.1-7 Approximately 15% of patients die within
the first few years, largely due to histological transforma-
tion or refractory disease. In contrast, the majority of
patients show prolonged survival without relapse and a
substantial number of patients never require treatment.
Currently, clinical factors captured in the Follicular
Lymphoma International Prognostic Index (FLIPI)8,9 and
the adjusted FLIPI210 are the primary prognostic tools uti-
lized to predict disease progression. FLIPI is based on eas-
ily available clinical data designed to offer an accurate yet
simple prognostic index. However, the biological behavior
of FL is likely determined by a more complex interaction
between tumor genetics, microenvironment and patient
characteristics.
Several gene expression profiling studies have under-
lined the major influence of characteristics of the non-
malignant tumor microenvironment on prognosis in FL.11,12
However, evaluation by immunohistochemistry (IHC) of
T-cell and macrophage populations for their prognostic
translational impact have produced valuable yet conflict-
ing results.13-25 Contradictory results are likely caused by
multiple factors, including variable patient selection, het-
erogeneity of treatments across cohorts,25 insufficient sta-
tistical power due to underrepresentation of poor outcome
patients, technical issues in IHC staining and inter-observ-
er variability in scoring. Previous IHC-based validation
studies of microenvironment cell populations by the
Lunenburg Lymphoma Biomarker Consortium (LLBC), in
both diffuse large B-cell Lymphoma (DLBCL) and FL, have
highlighted the poor reproducibility of manual scoring
even by experienced pathologists, and advocated comput-
er-assisted scoring as being the more reliable technique.26,27
Recently, the mutational spectrum of FL tumor cells and
their prognostic value have been reported.28-30 Most
notably, Pastore et al. demonstrated the value of combin-
ing mutation status with clinical FLIPI and performance
status to improve upon the prognostic value of FLIPI alone
(45-55%) to 64-72% for M7-FLIPI, with a comparable neg-
ative prognostic value.31 This method may also be valuable
for very high-risk FL cohorts, as reported by the same
group.32
The objective of the study herein by the LLBC consor-
tium was to critically assess, in a homogeneously treated
patient cohort, whether the previously implicated
microenvironmental and molecular markers of the tumor
have clinically relevant prognostic value. We hypothe-
sized that the microenvironmental and molecular markers
would be most prominent when we compared tissue sam-
ples of patients with an extremely poor prognosis (i.e.,
progression or death within 2 years, a well-established cri-
terion for poor prognosis in FL)33 with those with a very
favorable prognosis (a response to first-line treatment last-
ing >5 years). The LLBC gene panel incorporated the
molecular markers which were frequently mutated, and
were at that time published, as well as markers that were
rarely mutated such as FAS and MYD88,28-30 since with our
study design we hypothesized the ability to also reveal the
prognostic value of rare mutations.
To avoid interlaboratory technical variations and inter-
pretation, all assays were uniformly processed in a single
laboratory and IHC was scored using computer-assisted
technology based on a previous LLBC FL validation
study,27 and molecular analysis was performed using
established next-generation sequencing (NGS) procedures
for mutation and copy number analyses.  
Methods
Patient selection for an end of spectrum design
Tumor specimens of patients with FL, histologic grades 1, 2 and
3A were retrieved from the randomized Lymphoma Study
Association (LYSA) FL2000 study,4,6 the German Low-Grade
Lymphoma Study Group (GLSG) GLSG2000 study,3 and the St
Bartholomew’s Hospital Registry, London, UK. The patients
required treatment and the inclusion criteria in the trials were
comparable. All patients were treated with R-CHOP or R-CHOP-
like regimens, with or without interferon-α (IFN) maintenance for
2 years. Patients were selected upon the following criteria for an
end of spectrum design: (1) early failure (EF), defined as no remis-
sion or progression, or lymphoma-related death within 2 years
after start of first-line treatment, or (2) long remission (LR), defined
as a complete or partial remission lasting >5 years after starting 
first-line treatment. Patients that fell in between these criteria were
not included in this study. The availability of complete clinical
information at diagnosis, follow-up data until relapse, progression
or at least 5 years post-treatment if the patient was still in remis-
sion, and availability of formalin-fixed paraffin-embedded (FFPE)
diagnostic biopsy samples were prerequisites for inclusion.
Detailed clinical information on demographic parameters, staging
procedures, treatment regimens and outcome were collected by
the involved data centers (LYSA, GLSG and St Bartholomew’s
Hospital). 
Microenvironment analysis on tissue microarrays using
immunohistochemistry and automated image analysis
scoring 
Tissue microarrays (TMAs) were constructed centrally accord-
ing to LLBC validated protocols27 at the Department of Pathology,
Würzburg, Germany, from the biopsy part identified by the
pathologist (AR), using duplicate cores of 1mm diameter.  Three
µm slides were stained for CD3, CD4, CD8, CD68, CD163,
FOXP3, PD1, and P53 (Online Supplementary Table S1) according to
standard procedures at the Bartholomew’s Pathology Research
Laboratory, London, UK. 
A computerized system with automated scanning microscope
and computerized image analysis (Ariol SL-8, Leica Microsystems,
Wetzlar, Germany) was used for scoring as described in the LLBC
validation study.27 Macrophages and all T-cell populations were
scored for the whole core, and in the intrafollicular and interfollic-
ular areas separately, as described by Wahlin et al.22 Color and
shape class defined positive and negative nucleated cells (T-cell
classes), or positive and negative areas (macrophage classes).16
Cores with less than 50% scorable core surface (non-representa-
tive areas or tissue artifacts) were excluded and average scores of
duplicates were used when available. 
Using the Ariol software algorithm, CD3, CD4, CD8, PD1,
FOXP3 and p53 positive nucleated cells were scored as the per-
centage of all nucleated cells. For CD68 and CD163 the positive
area versus the whole area was scored to accommodate the large
size and long cytoplasmic extensions of macrophages as an opti-
mal determination of cell numbers. The typical perifollicular infil-
tration pattern of FOXP3 was scored manually by 3 observers,27
and was considered positive if at least 2 out of the 3 pathologists
(DdJ, AR and MC) identified and counted at least one rim of
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densely packed positive cells at the periphery of a follicle.14 All
histopathological assessments were carried out without insight
into the patient’s clinical data and outcome.
Gene mutation and copy number analysis using NGS 
DNA was extracted from FFPE cores with a QIAamp DNA FFPE
Tissue Kit (QIAGEN, Hilden, Germany) and quantified using a
Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Carlsbad, CA,
USA). 250ng DNA from each patient sample was sheared on a
Covaris S2 (Covaris Inc., Woburn, MA, USA), with settings adjust-
ed to DNA from FFPE tissue.34 NGS libraries were prepared using
KAPA Library Preparation kits (KAPA Biosystems, Inc.,
Wilmington, MA, USA). In short, uniquely 8-bp indexed adapters
(Roche NimbleGen, Madison, WI, USA.) were ligated to the FFPE-
extracted DNA, followed by size selection of fragments in the
range of 150 to 400bp.
One aliquot of this library was subjected to shallow whole-
genome sequencing (WGS) for genome-wide copy number analy-
sis,34 and another aliquot was subjected to hybrid capture target
enrichment (Roche NimbleGen, Madison, WI, USA) for mutation
analysis. Eight libraries were equimolarly pooled per capture. The
hybrid capture panel covers 122 exons (~50.000 base pairs) of 11
frequently mutated genes (KMT2D, CREBBP, MEF2B, EZH2,
EP300, BCL2, FAS, TNFRSF14, CARD11, TNFAIP3 and MYD88) in
the FL-LLBC-NGS target enrichment panel (Follicular Lunenburg
Lymphoma Biomarker Consortium NGS-panel, Online
Supplementary Table S2). All libraries were sequenced on a HiSeq
2000 (Illumina, San Diego, CA, USA); 50bp single-end for shallow
WGS and 125bp paired-end for mutation analysis. All sequence
lanes were multiplexed with up to 24 barcoded sample libraries.
Shallow WGS data was analyzed using the Bioconductor pack-
age QDNAseq (v1.5.1).34 For gene mutation analysis, variant call-
ing was performed by VarScan 2 (v2.3.7)35 using very strict criteria,
which excluded any synonymous mutations, any intronic muta-
tions with predicted low impact and all germline variants reported
in the Single Nucleotide Polymorphism database (dbSNP
build142). For prognostic analysis, only non-silent mutations (mis-
sense, nonsense, in-frame or frame-shift insertions and deletions)
were included. 
For detailed laboratory data analysis procedures see the Online
Supplementary Methods section. 
Ethical Committee statement
The study and protocols to obtain human archival tissues and
patient data were approved by the local ethical committee of the
VU University Medical Center, Amsterdam (FWA00017598) for all
collaborating centers and comply with the Code for Proper
Secondary Use of Human Tissue in The Netherlands. 
Statistics
Univariate and multivariate analyses were used to evaluate the
distribution of the biomarkers for the 2 cohorts. For microenviron-
ment analysis, biomarkers were included in the analysis using the
scoring categories as defined above, and the average of the bio-
marker score from 2 cores was used in the analysis. For mutation
analysis, the genes were included in the analysis as mutated or
wild-type. To correct for multiple comparisons, the Benjamini-
Hochberg method was used, and P-values of less than 0.05 were
considered significant. Patient characteristics were summarized
with descriptive statistics. The Fisher’s exact test was used to test
for association between pairs of categorical variables, and univari-
ate and multivariable logistic regression was used for the binary
outcome of cohorts. Odds ratios (OR) and 95% confidence inter-
vals (CI) were reported. The Wilcoxon rank-sum test was used to
assess a location shift in the distribution of continuous variables
between 2 groups. In a secondary analysis, optimal cut points for
8 continuous markers were determined using recursive partition-
ing models for a binary outcome. To evaluate agreement among
the 3 pathologists for the FOXP3 patterns the free-marginal κ sta-
tistics of Brennan and Prediger are reported with a bootstrap con-
fidence CI.36,37 Analyses were performed using SAS Software ver-
sion 9.3 (SAS Institute Inc., Cary, NC, USA; 2005) and R version
3.3.0 (R Core Team, Vienna, Austria; 2016).38
Results
Patient selection and immunohistochemical biomarker
assessment
A total of 122 patients fulfilled the selection criteria and
had biopsy material available that met the input require-
ments for both IHC and gene mutation analysis (EF, n=49
and LR, n=73). In 105 cases a complete set of IHC markers
was available (Online Supplementary Table S3). For NGS
analysis, DNA of sufficient quality and with sufficient
NGS read depth could be retrieved for 111 cases, resulting
in the complete molecular data for gene mutation analysis
and copy number profiles. 
For 96 of the 122 cases (79%) both IHC and molecular
data could be generated that met our quality criteria and
was included for downstream analysis. Table 1 shows the
clinical characteristics of the 96 patients (Online
Supplementary Table S4 provides the characteristics for all
122 patients, with marginal statistical differences for prog-
nostic subgroup representation). The FLIPI high-risk cate-
gory was overrepresented in the EF cohort (P=0.009),
underpinning the validity of the selection criteria for this
end of spectrum design. 
Impact of microenvironment T-cell and macrophage
cell populations by cohort 
The distribution of IHC markers per end of spectrum
prognostic subgroup analyzed in the whole core is shown
in Figure 1 and the Online Supplementary Table S5 (Online
Supplementary Table S6 shows the distribution of IHC
markers of the 105 cases). Statistically significant differ-
ences were found in the median percentage of CD8+ nucle-
ated cells (median EF vs. LR is 7.9% vs. 8.6%, P=0.011) and
CD163+ macrophages area (median EF vs. LR is 3.6% vs.
5.2%, P=0.038). In logistic regression analyses, the esti-
mated OR for CD8+ cells are 3.9 (95% CI: [1.5-12.1],
P=0.01) for a decrease of 10% CD8+ cells. For the CD163+
area the odds are 2.0 (95% CI: [1.1- 4.4], P=0.04) for a
decrease of 10% CD163+ area (Online Supplementary Table
S7). Adjusting for other IHC markers without the FLIPI
score in a multivariable model, only the CD8+ T cells
retained significance (OR=4.5, 95% CI: [1.1-21.2] P=0.04),
however, with the FLIPI score included they no longer
reached significance. No significant differences were
found for the other markers (CD3, CD4, CD68, CD163,
PD1, FOXP3 and p53) between the two cohorts (Online
Supplementary Table S7).
Since CD163 was binary scored as positive or negative,
a high overall score for the 2 prognostic subgroups might
be caused by a higher cell density and/or by larger individ-
ual cells. Visual assessment by two pathologists (DdJ, MC)
was performed and confirmed that the higher percentage
of positive areas was due to higher cell density. A second-
ary analysis using recursive partitioning was performed to
evaluate markers that could separate the 2 prognostic sub-
CD8, CD163, EZH2, chromosome 18, FL prognostic biomark-
ers
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groups and to determine the optimal cut points for the
identified markers for the whole core. The optimal cut
points were 12.6% and 6.3% for CD8+ and CD163+,
respectively. The percentage of patients with low levels of
both CD8+ T cells and CD163+ area (defined as lower than
the optimal cut points) was 79% (95% CI 64 – 91%) vs.
39% (95% CI 16 -52%) for EF (n=39) vs. LR (n=57)
(P<0.001). Similarly, results were obtained if the upper
quartiles were used instead of the optimal cut points
(12.2% (n=39) vs. 8.4% (n=57) for EF [79% (95% CI: 64 –
91%)] vs. LR [46% (95% CI: 32 – 59%)], P=0.001).   
Impact of spatial distribution and perifollicular pattern
of FOXP3 by prognostic subgroup 
The spatial distribution of T-cell populations and
macrophages has been claimed to be of greater influence
on prognosis than the overall numbers of infiltrating cells
and therefore intrafollicular and interfollicular populations
were assessed separately.14-17,19,22,39 However, in this series,
we could not validate this claim for most T-cell or
macrophage classes. Except in the univariate analysis of
the interfollicular population, differences in CD8+ cells and
CD163+ area were significant; CD8+ cells with an OR 3.6
(95% CI: [1.2-6.4], P=0.03) and CD163+ area 1.9 (95% CI:
[1.1-3.6], P=0.03). Only CD8+ interfollicular populations
have a minor influence in multivariate analysis excluding
the FLIPI score (OR 3.7, 95% CI [1.2-15.5], P<0.01) (Online
Supplementary Tables S8 and S9).
The perifollicular pattern of FOXP3+ T cells was scored
manually by 3 pathologists (DdJ, AR, BS). Agreement
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Table 1. Clinical characteristics of patients with all immunohistochemical and molecular markers available.
Total Early failure Long remission
n = 96 n = 39 n = 57
Group
Barts 8 (8%) 6 (15%) 2 (4%)
GLSG 80 (83%) 29 (74%) 51 (89%)
LYSA 8 (8%) 4 (10%) 4 (7%)
Age at diagnosis
Median (range) 58 (27-75) 61 (27-75) 58 (32-69)
< 60 50 (52%) 18 (46%) 32 (56%)
Sex
Female 47 (49%) 17 (44%) 30 (53%)
Grade
Grade 1, 2 75 (78%) 28 (72%) 47 (82%)
Grade 3A 6 (6%) 3 (8%) 3 (5%)
Missing 15 (16%) 8 (21%) 7 (12%)
Stage
Stage I-II 2 24%) 1 (3%) 1 (2%)
Stage III-IV 94 (87%) 38 (97%) 55 (96%)
Missing 1 (1%) 0 1 (2%)
B-symptoms
Absent 59 (61%) 23 (59%) 36 (63%)
Present 35 (36%) 16 (41%) 19 (33%)
Missing 2 (2%) 0 2 (4%)
ECOG PS
0 32 (33%) 13 (33%) 19 (33%)
1 58 (60%) 21 (54%) 37 (65%)
2 2 (2%) 2 (5%) 0 (0%)
3 1 (1%) 1 (3%) 0 (0%)
Missing 3 (2%) 2 (5%) 1 (2%)
FLIPI risk categories
Low 10 (10%) 1 (3%) 9 (16%)
Intermediate 35 (36%) 11 (28%) 24 (42%)
High 46 (48%) 26 (67%) 20 (36%)
Missing 5 (5%) 1 (3%) 4 (7%)
First-line therapy
R-CHOP 87 (91%) 34 (87%) 53 (93%)
R-CHVP-I 9 (9%) 5 (13%) 4 (7%)
Barts: Bartholomew’s Hospital Registry London, UK; GLSG: German low-grade Lymphoma Study Group; LYSA: the Lymphoma Study Association; ECOG: Eastern Cooperative
Oncology Group; PS: performance score; FLIPI: follicular lymphoma international prognostic index; R-CHOP: rituximab, cyclophosphamide, adriamycin, vincristine and pred-
nisone; R-CHVP-I: rituximab, cyclophosphamide, adriamycin, etoposide, prednisolone and interferon-α2a. 
between pathologists reached levels similar to the valida-
tion study (Brennan-Prediger estimate of 0.78 and 0.83 for
cores 1 and 2 in the study herein versus 0.85 for the valida-
tion study).29 The perifollicular pattern did not differ sig-
nificantly (P=0.46) between the 2 prognostic subgroups,
10/39 (26%) in the EF subgroup and 11/57 (19%) in the LR
subgroup (Online Supplementary Table S10).
Frequency distribution of chromosomal copy numbers
and gene mutations in FL
Shallow WGS resulted in high quality genome-wide
copy number aberration (CNA) plots for all cases. The
most common aberrations, detected in at least 10% of
patients, included complete or partial gains of chromo-
somes 1q, 2, 7, 8, 12 and 18 and losses of 1p, 6q and 10q
CD8, CD163, EZH2, chromosome 18, FL prognostic biomark-
ers
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Figure 1. Boxplots per immuunhistochemical marker. For CD4, CD8, CD3, FOXP3, PD1 and P53 they show the percentage of positive nucleated cells of all nucleated
cells, and for CD163 and CD68 they show the percentage of positive cell area of the total cell area. Early failure n=39, long remission n=57. 
(Figure 2 and Online Supplementary Table S11). The land-
scape of CNAs showed notable enrichment of FL-related
genes, including focal losses of TNFRSF14 (1p36.32),
TNFAIP3 (6p23.3) and FAS and PTEN (10q23.31) and focal
gains that harbor FL-related oncogenes, like BCL11A and
REL (2p16.1).
Genes included in the FL-LLBC-NGS target enrichment
panel showed non-synonymous mutations in at least 2 FL
cases (Figure 3 and Online Supplementary Table S12). BCL2,
a known target for aberrant somatic hypermutation
(aSHM) in FL, was most frequently mutated (88/96, 92%)
with 0 to 78 mutations per case. Chromatin modifying
genes KMT2D (71%) and CREBBP (67%) were mutated
with high frequency, and epigenetic modifiers EZH2
(18%), MEF2B (10%), EP300 (7%) at lower rates with
non-silent mutations in 1-4 of these chromatin modifying
genes in 90% of FL patients, consistent with the critical
role of epigenetic deregulation in the majority of FL. No
patterns of co-occurrence or mutual exclusivity were
observed.  Non-silent mutations were found in TNFRSF14
(30%), TNFAIP3 (7%), CARD11 (8%), FAS (2%) and
MYD88 (2%) (Table 2, Online Supplementary Table S13
shows the distribution of mutations of the 111 cases).
Impact of chromosomal copy numbers and gene 
mutations by prognostic subgroup 
The distribution of CNAs and gene mutations by prog-
nostic subgroup are shown in Figures 2 and 3. Statistically
significant differences after multiple testing correction
were only found for gain of chromosomal region
18p11.32-q21.33 (gain EF vs. LR 49% vs. 12%, P<0.001),
with an estimated OR in logistic regression analysis of
0.15 (95% CI: [0.05-0.44]) and for EZH2 mutation status
(unmutated EF vs. LR 90% vs. 72%, P<0.001) (Table 2).
The odds ratio for unmutated EZH2 was 14.53 (95%
CI:[2.06-635.92]). No significant impact was found for var-
ious markers, previously implicated as (borderline) prog-
nostic such as CREBBP (OR 0.55, 95% CI [0.20-1.45],
W.B.C. Stevens et al.
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Table 2. Distribution of gene mutation status by cohort (n=96).
Total Early failure Long remission OR P P
n=96 (%) n=39 (%) n=57 (%) [95% CI] (unadjusted) (adjusted)
BCL2
Mutated 88 (92) 37 (95) 51 (89) 0.46 [0.04 - 2.78] 0,47 0,9
Unmutated 8 (8) 2 (5) 6 (11)
KMT2D
Mutated 68 (71) 28 (72) 40 (70) 0.93 [0.34 - 2.47] > 0.99 > 0.99
Unmutated 28 (29) 11 (28) 17 (30)
CREBBP
Mutated 64 (67) 29 (74) 35 (61) 0.55 [0.20 - 1.45] 0,27 0,6
Unmutated 32 (33) 10 (26) 22 (39)
TNFRSF14
Mutated 29 (30) 10 (26) 19 (33) 1.44 [0.54 - 4.04] 0,5 0,9
Unmutated 67 (70) 29 (74) 38 (67)
MEF2B
Mutated 10 (10) 4 (10) 6 (11) 1.03 [0.22 - 5.33] > 0.99 > 0.99
Unmutated 86 (90) 35 (90) 51 (89)
EZH2
Mutated 17 (18) 1 (3) 16 (28) 14.53 [2.06 - 635.92] < 0.001 0,006
Unmutated 79 (82) 38 (97) 41 (72)
TNFAIP3
Mutated 7 (7) 1 (3) 6 (11) 4.41 [0.50 - 210.74] 0,23 0,6
Unmutated 89 (93) 38 (97) 51 (89)
EP300
Mutated 7 (7) 2 (5) 5 (9) 1.77 [0.27 - 19.52] 0,7 > 0.99
Unmutated 89 (93) 37 (95) 52 (91)
CARD11
Mutated 8 (8) 3 (8) 5 (9) 1.15 [0.21 - 7.89] > 0.99 > 0.99
Unmutated 88 (92) 36 (92) 52 (91)
FAS
Mutated 2 (2) 2 (5) 0 (0) 0.00 [0.00 - 3.62] 0,16 0,6
Unmutated 94 (98) 37 (95) 57 (100)
MYD88
Mutated 2 (2) 1 (3) 1 (2) 0.68 [0.01 - 54.63] > 0.99 > 0.99
Unmutated 94 (98) 38 (97) 56 (98)
OR: odds ratio; CI: confidence interval.
P=0.6), EP300 (OR 1.77, 95% CI [0.27-19.52], P>0.99),
CARD11 (OR 1.15, 95% CI [0.21-7.89], P>0.99) and
MEF2B (OR 1.03, 95% CI [0.22-5.33], P>0.99). 
Integrated modeling of immunohistochemical and
molecular analysis of the prognostic subgroups 
Correlation analysis was performed for molecular and
IHC markers, showing significant correlation between
mutated CREBBP status and higher level infiltrates of PD1
positive T cells (P<0.005), but not with CD4 and CD8 pos-
itive T cells (Figure 4A). TNFRSF14 mutation status
showed significant correlation with lower CD4 and CD8
positive T-cell infiltrates (P=0.037 and P=0.030) (Figure
4B). Microenvironmental populations were not signifi-
cantly differentially distributed for other molecular mark-
ers, including EZH2 (data not shown).
In a multivariable model combining the 4 markers, CD8,
CD163, gain chromosome 18 and EZH2mutation, that are
statistically significant in the univariate analysis, only the
gain of chromosome 18 (OR 0.27 (95% CI: [0.09,0.79],
P=0.019)) and EZH2 (OR 13.76 (95% CI: [2.53,264.94],
P=0.017)) retained significance. After incorporating the
FLIPI score into the model, gain of chromosome 18
(P=0.018) and EZH2 (P=0.036) (Table 3) retained signifi-
cance.
Discussion 
This LLBC study is, as far as we know, the first to com-
prehensively explore the combined prognostic impact of
microenvironment T-cell and macrophage infiltration and
CD8, CD163, EZH2, chromosome 18, FL prognostic biomark-
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Figure 2. Distribution and significance of copy number gains and losses by subgroup. Top panel: Percentages of gains (top; green) and losses (bottom; red) in early
failure (EF, n=39) and long remission (LR, n=57) per chromosomal region. X-axis: chromosomal regions, ordered by genomic coordinates of chromosomes 1 to 22.
Y-axis: percentage of cases showing CNAs. Vertical dotted lines: boundaries between chromosomes.  Bottom panel: statistical significance of differences in frequen-
cies of gains (top) and losses (bottom) between cohorts. X-axis: chromosomal regions, ordered by genomic coordinates of chromosomes 1 to 22. Y-axis: P-value (blue)
and false discovery rate (FDR; yellow). Horizontal dotted lines show the threshold of significance for P (0.05) and FDR (0.1), based on a Wilcoxon rank-sum test with
10 000 permutations.   
Table 3. Odds ratio (OR) (95% Cl) for a 10% change in the immunohistochemical markers and absent or present molecular markers in univariate
analysis, and multivariate analysis without and with the FLIPI.
Univariate Multivariable without FLIPI Multivariable with FLIPI
OR P OR P OR P
(95% Cl) (95% Cl) (95% Cl)
%CD8 3.86 0.01 3.15 0.064 2.58 0.13
(1.48, 12.13) (1.03, 11.87) (0.83, 10.02)
%CD163 2.01 0.04 1.54 0.29 1.43 0.38
(1.11, 4.37) (0.75, 3.83) (0.69, 3.52)
CHR 18 0.15 <0.001 0.27 0.019 0.24 0.018
(0.05, 0.39) (0.09, 0.79) (0.07, 0.75)
EZH2 14.83 0.011 13.76 0.017 9.99 0.036
(2.82, 274.07) (2.35, 264.94) (1.69, 192.73)
FLIPI high 0.28 0.005 0.36
(0.11, 0.66) (0.12, 0.98)
CI: confidence interval; FLIPI: follicular lymphoma international prognostic index.
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tumor genetics of FL patients with extremely poor out-
come (EF) versus those with a prolonged remission (LR).
We show poor outcome to be characterized by a lower
number of CD8+ T cells, a smaller CD163+ macrophage
area (indicative of fewer macrophages), wild-type EZH2
and a copy number gain of chromosome 18. These obser-
vations, in part, confirm previous studies. The gain of
chromosome 18, despite its statistically strong prognostic
value, has not been reported previously. Equally impor-
tant, cellular densities of various other cell populations,
such as PD1+ T follicular helper (TFH) cells and FOXP3+ T
regulatory (Treg) cells, previously claimed to predict clini-
cal outcome, were not confirmed in our study.16,22,24,39-41
This study was specifically designed to verify the
impact of previously published IHC and molecular mark-
ers in FL in the rituximab-chemotherapy era. Therefore,
we implemented a dedicated study design to reduce noise
such that all cases were retrieved from clinical trials and
registries which guaranteed complete clinical information
at presentation and detailed treatment information. This
allowed us to make a homogeneously treated patient
selection, with subgroups at the extreme ends of the prog-
nostic spectrum, the EF and the LR subgroups. By balanc-
ing inclusion of the rare EF subgroup, we maximized the
sensitivity to observe clinically relevant differences in the
microenvironment and mutations, while allowing an over-
all relatively small patient cohort. To reduce inter-observer
variability, the validated quantitative computerized IHC
scoring method of the TMA was implemented, which has
previously been shown to be more reproducible than any
semi-quantitative method.27
For microenvironment populations, our results regard-
ing the CD163+ area validate those of Kridel et al., show-
ing that a higher CD163+ pixel count or CD163+ area are
independent predictors of prolonged progression-free sur-
vival (PFS) in patients treated with R-CHOP (P=0.011-
0.030), while the CD68+ macrophages population did not
have a significant impact by pixel count or area.42 Previous
reports provided conflicting data for CD68+ macrophages,
suggesting correlation with either adverse17,39,43,44 or favor-
able outcome.45 Differences in scoring methods and varia-
tions in treatment characteristics may explain these dis-
crepancies. 
This LLBC study also showed that a lower percentage of
CD8+ cytotoxic T cells in the whole TMA core and inter-
follicular areas was associated with EF after treatment
with rituximab-chemotherapy. This confirms findings in
several series using computerized scoring or flow cytome-
try of cell suspensions, both in the rituximab era and pre-
rituximab era.15,22,46 However, inconsistent results were
obtained in studies using manual scoring,14,18,47 corroborat-
ing the need for a reliable scoring method of CD8+ T cells. 
None of the other T-cell markers, including CD3, CD4,
PD1 and FOXP3 demonstrated a significant prognostic
impact. Debates mostly focus on PD1+ cells, FOXP3+ cells
and perifollicular patterns of FOXP3 positive T cells, with
conflicting results being published. However, the positive
prognostic value of PD1+ cells was seen in studies in
which only  some of  the patients received rituximab,16,22
whereas in studies in which the majority of patients were
treated with rituximab-chemotherapy, either no effect or
a negative effect was reported.39,41
Frequencies of mutations and distribution of alterations
in hotspots and functional domains of the tested genes are
largely in line with those previously reported.28,31,48-50
Almost all FLs are reported to have mutations in 1 or more
histone-modifying gene, such as KMT2D (reported as 76-
89%), CREBBP (reported as 33-68%), MEF2B (reported as
15%), EP300 (reported as 9-15%) and EZH2 (reported as
7-26%).49 Histone-modifying genes exert their function
largely indirectly via co-activation of various transcription
factors, and as such their specific role in B-cell oncogenesis
and immunological functions is difficult to predict.51 Gene
expression analysis has suggested that mutated CREBBP
may downregulate major histocompatibility complex
(MHC) class II genes, resulting in impaired T-cell activa-
tion and possibly lower T-cell levels in tumor samples.49
This hypothesis could not be supported in the study here-
in, which showed no association of CREBBPmutation sta-
tus and total numbers of T cells or specific subsets, apart
from an association of CREBBP mutated status with high-
er numbers of PD1 positive T cells. It should be noted,
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Figure 3. Distribution of mutations in 11 genes by subgroup. Each column represents an individual case. Genes are clustered based on functional category and
mutations are color-coded based on effect prediction. Mutation frequencies for each gene by cohort are shown in the bar graph on the right. EF: early failure; LR:
long remission.
however, that the differences, albeit statistically signifi-
cant, take place in a very narrow dynamic range. KMT2D,
which was mutated in 70% of both EF and LR cases,
showed a strong correlation to both CD8 and CD163 with
high levels of both markers in wild-type cases. KMT2D is
known to decrease apoptosis and increase B-cell prolifera-
tion both directly and indirectly in germinal center B
cells.52 Conditional mouse models indicate a role in plasma
cell and germinal center differentiation.53 Regulatory alter-
ations, impacting on immunological interactions with T
cells or macrophages have not been described, however.
In line with this, it is less remarkable that the mutation
status of TNFRSF14, a protein that is directly involved in
immune response regulation, does correlate with CD4+
and CD8+ T-cell infiltration in tumor samples. 
By shallow WGS, copy number profiles of all tumors
were studied in both prognostic groups. Of all previously
published numerical alterations in FL, only gain of chro-
mosome 18 stood out as an independent prognostic mark-
er. Our results confirm EZH2 as a strong prognostic mark-
er in FL, with wild-type gene status associated with poor
disease outcome (EF),31,32 but other markers, such as EP300
and TNFRSF14, which have been implicated to have a sig-
nificant, though minor, impact on prognosis, were not
substantiated in our study.31,54 This is likely due to selection
bias and relative underrepresentation of poor prognosis
patients in previous series for which our study design was
specifically optimized. This LLBC study design precludes
integration of a complete multifactorial prognostic model
such as the M7-FLIPI index, however, the prognostic trend
of EZH2 as reported by Pastore et al. follows the same
direction as in our study, where statistical significance is
reached and lack of significance of 4 other markers is con-
firmed.
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Figure 4. Correlation molecular markers and IHC markers. A: CREBBP B: TNFRSF14. Blue bars are mutated, gray bars are wild-type. On the X-axis the number of
cases per IHC marker, on the Y-axis the percentages of positive cells or area. 
The pertinent question is whether these findings on the
prognostic value of microenvironment populations and
genomic alterations can be translated to application in daily
clinical practice. The mutations in EZH2 are largely clus-
tered in codon Y646 (Online Supplementary Figure S1) and are
therefore technically very easily amenable to simple poly-
merase chain reaction (PCR) techniques,55 while chromoso-
mal gains can be monitored using fluorescence in situ
hybridization (FISH) or NGS.56,57 This signifies that EZH2
mutation status and chromosome 18 gain have a high
potential for clinical implementation, in contrast to the
microenvironment population markers CD8 and CD163.
With current techniques, even if optimized, the absolute
quantitative differences are too small between these 2
extreme cohorts to become a powerful and clinically useful
tool for the scores around the cut point. At best the predic-
tion of the extremes can be used for this purpose. 
In conclusion, the literature with regard to IHC prognos-
tic markers in FL has produced highly conflicting results,
and concerning mutation analysis, only very limited data
are currently available on prognostic impact. By making
use of a specialized study design and a homogeneously rit-
uximab-chemotherapy treated group of patients, we can
now confirm that lower percentages of CD8+ T cells,
CD163+ M2 macrophage areas, EZH2 wild-type status
and gain of chromosome 18 in the initial tumor biopsy
specimen predict a poor prognosis in FL for this treatment
cohort. Of equal importance, in the study herein we could
not substantiate the previously reported claims on the
prognostic impact of the other most commonly mutated
genes, such as TNFRSF14 and EP300, of T-cell populations
and classes of macrophages, as well as a perifollicular dis-
tribution of FOXP3+ T cells for patients treated with R-
CHOP (-like).14,16,18,22,24,31,39-41,54 Moreover, the study herein
provides further insight into the relationship between
gene mutation status and the most relevant microenviron-
mental populations in FL.
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